Athero-protective Effects of High Density Lipoproteins (HDL): An ODE Model of the Early Stages of Atherosclerosis

Bulletin of Mathematical Biology

Volumn 76, Issue 5, 2014, Pages 1117-1142

  Cohen, Anna ^a   Myerscough, Mary R ^a   Thompson, Rosemary S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cardiovascular disease; Dynamical systems

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; BIOLOGICAL MODEL; FOAM CELL; HUMAN; IMMUNOLOGY; MACROPHAGE;

ATHEROSCLEROSIS; CHOLESTEROL; FOAM CELLS; HUMANS; LIPOPROTEINS, HDL; MACROPHAGES; MODELS, CARDIOVASCULAR; MODELS, IMMUNOLOGICAL;

EID: 84899961333     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-014-9948-4     Document Type: Article

References (41)

1. Aicher, B. O., Haser, E. K., Freeman, L. A., Carnie, A. V., Stonik, J. A., Wang, X., Remaley, A. T., Kato, G. J., & Canon, R. O. III (2012). Diet-induced weight loss in overweight or obese women and changes in high-density lipoprotein levels and function. Obesity, 20(10), 2057-2062.
2. Ameli, S., Hultgardh-Nilsson, A., Cercek, B., Shah, P. K., Forrester, J. S., Ageland, H., & Nilsson, J. (1994). Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation, 90(4), 1935-1941.
3. Barter, P. J., Nicholls, S., Rye, K.-A., Anantharamaiah, G., Navab, M., & Fogelman, A. M. (2004). Anti-inflammatory properties of HDL. Circ. Res., 95(8), 764-772.
4. Berrougui, H., Isabelle, M., Cloutier, M., Grenier, G., & Khalil, A. (2007). Age-related impairment of HDL-mediated cholesterol efflux. J. Lipid Res., 48(2), 328-336.
5. Cobbold, C. A., Sherratt, J. A., & Maxwell, S. R. J. (2002). Lipoprotein oxidation and its significance for atherosclerosis: a mathematical approach. Bull. Math. Biol., 64, 65-95.
6. Dansky, H. M., & Fisher, E. A. (1999). High-density lipoprotein and plaque regression: the good cholesterol gets even better. Circulation, 100(17), 1762-1763.
7. Duffy, D., & Rader, D. J. (2006). Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation, 113(8), 1140-1150.
8. Ellison, R. C., Zhang, Y., Qureshi, M. M., Knox, S., Arnett, D. K., & Province, M. A. (2004). Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am. Heart J., 147(3), 529-535.
9. Eriksson, M., Carlson, L. A., Miettinen, T. A., & Angelin, B. (1999). Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Circulation, 100(6), 594-598.
10. Feig, J. E., Rong, J. X., Shamir, R., Sanson, M., Vengrenyuk, Y., Liu, J., Rayner, K., Moore, K., Garabedian, M., & Fisher, E. A. (2011). HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc. Natl. Acad. Sci. USA, 108(17), 7166-7171.
11. Hansson, G. K., & Libby, P. (2006). The immune response in atherosclerosis: a double-edged sword. Nat. Immunol., 6, 508-519.
12. Joy, T., & Hegele, R. (2008). Is raising HDL a futile strategy for atheroprotection?. Nat. Rev. Drug Discov., 7, 143-155.
13. Kennedy, M. A., Barrera, G. C., Nakamura, K., Baldan, A., Tarr, P., Fishbein, M. C., Frank, J., Francone, O. L., & Edwards, P. A. (2005). ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metabolism, 1, 121-131.
14. Kharbanda, R., & MacAllister, R. (2005). The atherosclerosis time-line and the role of the endothelium. Curr. Medicine Chem., 5, 47-52.
15. Kunjathoor, V. V., Febbraio, M., Podrez, E. A., Moore, K. J., Andersson, L., Koehn, S., Rhee, J. S., Silverstein, R., Hoff, H. F., & Freeman, M. W. (2002). Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem., 277(51), 49982-49988.
16. Lee, J. M., & Choudhury, R. P. (2007). Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart, 93, 559-564.
17. Lendon, C. L., Davies, M. J., Born, G. V. R., & Richardson, P. D. (1991). Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis, 87(1), 87-90.
18. Libby, P., & Ridker, P. M. (2006). Inflammation and atherothrombosis: from population biology and bench research to clinical practice. J. Am. Coll. Cardiol., 48, A33-A46.
19. Libby, P., Ridker, P. M., & Maseri, A. (2002). Inflammation and atherosclerosis. Circulation, 105, 1135-1143.
20. Linsel-Nitschke, P., & Tall, A. (2005). HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov., 4, 193-205.
21. Liu, H., Shi, B., Huang, C.-C., Eksarko, P., & Pope, R. M. (2008). Transcriptional diversity during monocyte to macrophage differentiation. Immunol. Lett., 117(1), 70-80.
22. Llodrá, J., Angeli, V., Liu, J., Trogan, E., Fisher, E. A., & Randolph, G. J. (2004). Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive plaques. Proc. Natl. Acad. Sci. USA, 101(32), 11779-11784.
23. Lusis, A. J. (2000). Atherosclerosis. Nature, 407, 233-241.
24. Morton, J., Bao, S., Celermajer, D. S., Ng, M. K., & Bursill, C. A. (2013). Strikingly different atheroprotective effects of apoliprotein A-I in early-stage versus late-stage atherosclerosis. Circulation, 128, A15785.
25. Navab, M., Anantharamaiah, G., Reddy, S. T., Lenten, B. J. V., & Fogelman, A. M. (2009). HDL as a biomarker, potential therapeutic target, and therapy. Diabetes, 58(12), 2711-2717.
26. Nicholls, S. J. (2012). The aim-high (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides: impact on global health outcomes) trial. To believe or not to believe? J. Am. Coll. Cardiol., 59(23), 2065-2067.
27. Nicholson, A. C., Han, J., Febbraio, M., Silverstein, R. L., & Hajjar, D. P. (2001). Role of CD36, the macrophage class B scavenger receptor, in atherosclerosis. Ann. N. Y. Acad. Sci., 947(1), 224-228.
28. Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., Tuzcu, E. M., & ILLUSTRATE Investigators (2007). Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med., 356(13), 1304-1316.
29. Ougrinovskaia, A., Thompson, R. S., & Myerscough, M. R. (2010). An ODE model of early stages of atherosclerosis: mechanisms of the inflammatory response. Bull. Math. Biol., 72(6), 1534-1561.
30. Parolini, G. C. C., & Marchesi, M. (2009). HDL therapy for the treatment of cardiovascular diseases. Curr. Vasc. Pharmacol., 7(4), 550-556.
31. Reis, E. D., Li, J., Fayad, Z. A., Rong, J. X., Hansoty, D., Aguinaldo, J.-G., Fallon, J. T., & Fisher, E. A. (2001). Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model. J. Vasc. Surg., 34(3), 541-547.
32. Rong, J. X., Li, J., Reis, E. D., Choudhury, R. P., Dansky, H. M., Elmalem, V. I., Fallon, J. T., Breslow, J. L., & Fisher, E. A. (2001). Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation, 104(20), 2447-2452.
33. Ross, R. (1999). Atherosclerosis-an inflammatory disease. N. Engl. J. Med., 340, 115-126.
34. Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007). High-density lipoprotein as a therapeutic target: a systematic review. JAMA J. Am. Med. Assoc., 298(7), 786-798.
35. Sirtori, C., & Fumagalli, R. (2006). LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention: a lesson from cholesterol turnover studies and others. Atherosclerosis, 186, 1-11.
36. Soma, M. R., Donetti, E., Parolini, C., Sirtori, C. R., Fumagalli, R., & Franceschini, G. (1995). Recombinant apolipoprotein A-I Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ. Res., 76(3), 405-411.
37. Stary, H. C., Chandler, A. B., Glagov, S., Guyton, J. R., Insull, W., Rosenfeld, M. E., Schaffer, S. A., Schwartz, C. J., Wagner, W. D., & Wissler, R. W. (1994). A definition of initial, fatty streak and intermediate lesions of atherosclerosis-a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 89(5), 2462-2478.
38. Thompson, P. D., & Rader, D. J. (2001). Does exercise increase HDL cholesterol in those who need it the most? Arterioscler. Thromb. Vasc. Biol., 21(7), 1097-1098.
39. Trogan, E., Feig, J. E., Dogan, S., Rothblat, G. H., Angeli, V., Tacke, F., Randolph, G. J., & Fisher, E. A. (2006). Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc. Natl. Acad. Sci. USA, 103(10), 3781-3786.
40. White, C., Datta, G., Zhang, Z., Gupta, H., Garber, D., Mishra, V., Palgunachari, M., Handattu, S., Chaddha, M., & Anantharamaiah, G. (2008). HDL therapy for cardiovascular diseases: the road to HDL mimetics. Curr. Atheroscl. Rep., 10, 405-412.
41. Williams, K. J., Feig, J. E., & Fisher, E. A. (2008). Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat. Clin. Pract. Cardiovasc. Med., 5(2), 91-102.